JP7636388B2 - サイクリン依存性キナーゼ７（ｃｄｋ７）の分解誘導剤およびその使用 - Google Patents

サイクリン依存性キナーゼ７（ｃｄｋ７）の分解誘導剤およびその使用 Download PDF

Info

Publication number
JP7636388B2
JP7636388B2 JP2022506574A JP2022506574A JP7636388B2 JP 7636388 B2 JP7636388 B2 JP 7636388B2 JP 2022506574 A JP2022506574 A JP 2022506574A JP 2022506574 A JP2022506574 A JP 2022506574A JP 7636388 B2 JP7636388 B2 JP 7636388B2
Authority
JP
Japan
Prior art keywords
carbamate
methyl
optionally substituted
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022506574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543231A5 (https=
JP2022543231A (ja
Inventor
グワンイェン ドゥ，
ナサナエル エス． グレイ，
ティンフー ジャン，
ジーシャン ヒー，
ニコラス クフャトコフスキ，
ジー ジャン，
Original Assignee
ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド filed Critical ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド
Publication of JP2022543231A publication Critical patent/JP2022543231A/ja
Publication of JP2022543231A5 publication Critical patent/JP2022543231A5/ja
Application granted granted Critical
Publication of JP7636388B2 publication Critical patent/JP7636388B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2022506574A 2019-08-05 2020-08-04 サイクリン依存性キナーゼ７（ｃｄｋ７）の分解誘導剤およびその使用 Active JP7636388B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882958P 2019-08-05 2019-08-05
US62/882,958 2019-08-05
PCT/US2020/044815 WO2021026109A1 (en) 2019-08-05 2020-08-04 Degraders of cyclin-dependent kinase 7 (cdk7) and uses thereof

Publications (3)

Publication Number Publication Date
JP2022543231A JP2022543231A (ja) 2022-10-11
JP2022543231A5 JP2022543231A5 (https=) 2023-08-02
JP7636388B2 true JP7636388B2 (ja) 2025-02-26

Family

ID=74503218

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506574A Active JP7636388B2 (ja) 2019-08-05 2020-08-04 サイクリン依存性キナーゼ７（ｃｄｋ７）の分解誘導剤およびその使用

Country Status (8)

Country Link
US (1) US12491251B2 (https=)
EP (1) EP4010336B1 (https=)
JP (1) JP7636388B2 (https=)
CN (1) CN114174281B (https=)
AU (1) AU2020324408B2 (https=)
CA (1) CA3149374A1 (https=)
ES (1) ES3031581T3 (https=)
WO (1) WO2021026109A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
USRE50776E1 (en) 2015-03-27 2026-02-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
US12281126B2 (en) 2018-12-28 2025-04-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
WO2021133601A1 (en) * 2019-12-24 2021-07-01 Dana-Farber Cancer Institute, Inc. The combination of cyclin dependent kinase 7 inhibitor and immunotherapy for treatment of cancer
AU2022207648A1 (en) 2021-01-13 2023-07-27 Monte Rosa Therapeutics Ag Isoindolinone compounds
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
CN113234081A (zh) * 2021-05-27 2021-08-10 东南大学 一种吡咯并吡唑衍生物与dmpeda做脲的制备方法
US20240343732A1 (en) * 2021-05-28 2024-10-17 Qurient Co., Ltd. Compounds for degradation of cyclin-dependent kinase 7(cdk7)
CN116396295A (zh) * 2023-04-04 2023-07-07 合肥工业大学 一种基于protac的plk1降解剂的合成方法
WO2025252190A1 (en) * 2024-06-07 2025-12-11 Cullgen Inc. Targeted degraders of werner syndrome recq helicase
CN119119072B (zh) * 2024-08-23 2025-10-03 武汉大学 一种用于检测和降解ERα的诊疗一体化ERαPROTACs化合物及其制备方法与应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004505977A (ja) 2000-08-10 2004-02-26 フアルマシア・イタリア・エツセ・ピー・アー キナーゼ阻害剤としての二環式ピラゾール、それらを製造するための方法およびそれらを含む医薬組成物
JP2018502098A (ja) 2014-12-23 2018-01-25 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
JP2018531983A (ja) 2015-11-02 2018-11-01 イエール ユニバーシティ タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法
CN109516989A (zh) 2017-09-17 2019-03-26 上海美志医药科技有限公司 一类抑制并降解cdk的化合物
JP2019514882A (ja) 2016-04-22 2019-06-06 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ９（ｃｄｋ９）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｃｄｋ９の分解および使用法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2013039854A1 (en) 2011-09-15 2013-03-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
WO2013070688A1 (en) * 2011-11-11 2013-05-16 Yale University Reprogramming urokinase into an antibody-recruiting anticancer agent
KR102668696B1 (ko) 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
EP3270917A4 (en) * 2015-03-18 2018-08-08 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
MX394157B (es) * 2015-06-15 2025-03-24 Ube Corp Derivado de dihidropirrolopirazol sustituido.
CN109790143A (zh) * 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2018106870A1 (en) * 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004505977A (ja) 2000-08-10 2004-02-26 フアルマシア・イタリア・エツセ・ピー・アー キナーゼ阻害剤としての二環式ピラゾール、それらを製造するための方法およびそれらを含む医薬組成物
JP2018502098A (ja) 2014-12-23 2018-01-25 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
JP2018531983A (ja) 2015-11-02 2018-11-01 イエール ユニバーシティ タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法
JP2019514882A (ja) 2016-04-22 2019-06-06 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ９（ｃｄｋ９）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｃｄｋ９の分解および使用法
CN109516989A (zh) 2017-09-17 2019-03-26 上海美志医药科技有限公司 一类抑制并降解cdk的化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUANG, Hai-Tsang et al.，A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader，Cell Chemical Biology，2018年，Vol.25, No.1，pp.88-99，DOI:10.1016/j.chembiol.2017.10.005
OLSON, C. M. et al.，Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype，Cell Chemical Biology，2019年，Vol.26, No.6，pp.792-803，DOI:10.1016/j.chembiol.2019.02.012

Also Published As

Publication number Publication date
EP4010336B1 (en) 2025-04-02
US20220280649A1 (en) 2022-09-08
AU2020324408B2 (en) 2026-03-12
EP4010336A4 (en) 2023-08-23
CA3149374A1 (en) 2021-02-11
ES3031581T3 (en) 2025-07-09
WO2021026109A1 (en) 2021-02-11
CN114174281B (zh) 2025-02-07
JP2022543231A (ja) 2022-10-11
EP4010336A1 (en) 2022-06-15
AU2020324408A1 (en) 2021-12-16
US12491251B2 (en) 2025-12-09
CN114174281A (zh) 2022-03-11

Similar Documents

Publication Publication Date Title
JP7636388B2 (ja) サイクリン依存性キナーゼ７（ｃｄｋ７）の分解誘導剤およびその使用
US20230338373A1 (en) Inhibitor of indoleamine-2,3-dioxygenase (ido)
US10975055B2 (en) Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
US12551563B2 (en) ERK5 degraders as therapeutics in cancer and inflammatory diseases
US20250255839A1 (en) Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
EP4362933A1 (en) Complement inhibition
HK1225383A1 (zh) 二氮杂环庚烷衍生物及其用途
HK1224140A1 (zh) 转录因子抑制剂及其用途
JP2025098013A (ja) がん幹細胞を標的化するがん治療
US12109207B2 (en) Methods of using 4(1H)-quinolone derivatives
HK1256417A1 (zh) 氰基噻吩并三唑并二氮杂环庚三烯及其用途
JP2017520586A (ja) ハリコンドリン類似体の合成およびその使用
KR20220098732A (ko) 요법, 특히 myd88 돌연변이된 질환에 사용하기 위한 hck 억제제로서의 피라졸로피리미딘 유도체
US10336724B2 (en) D-amino acid oxidase inhibitors and therapeutic uses thereof
CN108884054A (zh) 用于治疗增殖性疾病的化合物
US12478616B2 (en) PI3K inhibitors and uses thereof
JP2025513813A (ja) ヒストン脱アセチル化酵素６（ｈｄａｃ６）の阻害
US12521410B2 (en) Compounds and pharmaceutical uses thereof
US20230382865A1 (en) Histone demethylase 5 inhibitors and uses thereof
US20170313736A1 (en) Mutagenic nucleoside analogs and uses thereof
US10273264B2 (en) Cortistatin analogues and syntheses and uses thereof
HK40041778A (en) Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
HK1228196A1 (en) Dihydropteridinone derivatives and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230725

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230725

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250213

R150 Certificate of patent or registration of utility model

Ref document number: 7636388

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150